Global Ustekinumab Injection Market Growth 2026-2032
The global Ustekinumab Injection market size is predicted to grow from US$ 15590 million in 2025 to US$ 23760 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.
Ustekinumab Injection is a formulation containing ustekinumab as the active ingredient, which is a fully human IgG1? monoclonal antibody. It works by specifically binding to the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby blocking their interaction with receptors and inhibiting the activation of associated inflammatory signaling pathways. This injectable medication is commonly indicated for the treatment of immune-mediated diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the global production volume of ustekinumab injection was 3.9 million syringes, with an average price of USD 3,852 per syringe.
Market Overview
The ustekinumab market has maintained steady growth in recent years, driven by increasing demand from patients for effective and low-frequency dosing regimens. Growth is observed not only in established indications but also supported by clinical expansion into new therapeutic areas and the gradual introduction of biosimilars, contributing to overall market development.
Regional Market Landscape
Globally, the United States accounts for 50% of the market, Europe for 20%, Asia for 15%, and other regions for 15%, reflecting a market structure centered on North America and Europe, while the Asian market is rapidly penetrating and gradually forming a strong growth momentum.
Key Manufacturers and Industry Competition
The originator maintains a dominant position worldwide, but competition has intensified with the expiration of patents and the entry of biosimilars. Multiple international and regional companies are competing in the development, production, and commercialization of both originator and biosimilar products, while collaboration and licensing strategies are used to optimize market positioning.
Technological Trends and Innovation Directions
Technological innovation is primarily focused on high-concentration formulations and convenient administration methods, alongside optimization of biosimilars and research into combination therapy strategies. These innovations improve treatment adherence and provide technical support for expansion into new indications, facilitating broader clinical adoption.
Policy and Industry Development Drivers
Supportive healthcare policies and accelerated biosimilar approvals are key drivers of market growth, alongside increasing patient acceptance of innovative therapies. Regulatory optimization and industry guidance together promote the market’s standardization and scale expansion.
Future Outlook
Looking ahead, the ustekinumab market is expected to maintain steady growth amid intensified competition, with potential increases in market concentration. Expansion into new indications and personalized therapies will be major growth drivers, while technological innovation, regional penetration, and policy support will collectively shape the future market landscape.
LP Information, Inc. (LPI) ' newest research report, the “Ustekinumab Injection Industry Forecast” looks at past sales and reviews total world Ustekinumab Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ustekinumab Injection sales for 2026 through 2032. With Ustekinumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab Injection industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ustekinumab Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Ustekinumab Injection is a formulation containing ustekinumab as the active ingredient, which is a fully human IgG1? monoclonal antibody. It works by specifically binding to the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby blocking their interaction with receptors and inhibiting the activation of associated inflammatory signaling pathways. This injectable medication is commonly indicated for the treatment of immune-mediated diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the global production volume of ustekinumab injection was 3.9 million syringes, with an average price of USD 3,852 per syringe.
Market Overview
The ustekinumab market has maintained steady growth in recent years, driven by increasing demand from patients for effective and low-frequency dosing regimens. Growth is observed not only in established indications but also supported by clinical expansion into new therapeutic areas and the gradual introduction of biosimilars, contributing to overall market development.
Regional Market Landscape
Globally, the United States accounts for 50% of the market, Europe for 20%, Asia for 15%, and other regions for 15%, reflecting a market structure centered on North America and Europe, while the Asian market is rapidly penetrating and gradually forming a strong growth momentum.
Key Manufacturers and Industry Competition
The originator maintains a dominant position worldwide, but competition has intensified with the expiration of patents and the entry of biosimilars. Multiple international and regional companies are competing in the development, production, and commercialization of both originator and biosimilar products, while collaboration and licensing strategies are used to optimize market positioning.
Technological Trends and Innovation Directions
Technological innovation is primarily focused on high-concentration formulations and convenient administration methods, alongside optimization of biosimilars and research into combination therapy strategies. These innovations improve treatment adherence and provide technical support for expansion into new indications, facilitating broader clinical adoption.
Policy and Industry Development Drivers
Supportive healthcare policies and accelerated biosimilar approvals are key drivers of market growth, alongside increasing patient acceptance of innovative therapies. Regulatory optimization and industry guidance together promote the market’s standardization and scale expansion.
Future Outlook
Looking ahead, the ustekinumab market is expected to maintain steady growth amid intensified competition, with potential increases in market concentration. Expansion into new indications and personalized therapies will be major growth drivers, while technological innovation, regional penetration, and policy support will collectively shape the future market landscape.
LP Information, Inc. (LPI) ' newest research report, the “Ustekinumab Injection Industry Forecast” looks at past sales and reviews total world Ustekinumab Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ustekinumab Injection sales for 2026 through 2032. With Ustekinumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ustekinumab Injection industry.
This Insight Report provides a comprehensive analysis of the global Ustekinumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ustekinumab Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Original Drug
- Biosimilars
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Meiji
- Johnson & Johnson
- Alvotech
- Fuji Pharma
- Mitsubishi
- Tanabe
- Stada
- EPIRUS
- BioPharma
- Formycon
- NeuClone
- Amgen
- Sandoz
- Biocon Biologics
- Huadong Medicine
- What is the 10-year outlook for the global Ustekinumab Injection market?
- What factors are driving Ustekinumab Injection market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Ustekinumab Injection market opportunities vary by end market size?
- How does Ustekinumab Injection break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ustekinumab Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ustekinumab Injection by Country/Region, 2021, 2025 & 2032
2.2 Ustekinumab Injection Segment by Type
2.2.1 Original Drug
2.2.2 Biosimilars
2.2.3 Ustekinumab Injection Sales by Type
2.2.3.1 Global Ustekinumab Injection Sales Market Share by Type (2021-2026)
2.2.3.2 Global Ustekinumab Injection Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Ustekinumab Injection Sale Price by Type (2021-2026)
2.3 Ustekinumab Injection Segment by Application
2.3.1 Plaque Psoriasis
2.3.2 Psoriatic Arthritis
2.3.3 Crohn’s Disease
2.3.4 Ulcerative Colitis
2.3.5 Others
2.3.6 Ustekinumab Injection Sales by Application
2.3.6.1 Global Ustekinumab Injection Sale Market Share by Application (2021-2026)
2.3.6.2 Global Ustekinumab Injection Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Ustekinumab Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ustekinumab Injection Breakdown Data by Company
3.1.1 Global Ustekinumab Injection Annual Sales by Company (2021-2026)
3.1.2 Global Ustekinumab Injection Sales Market Share by Company (2021-2026)
3.2 Global Ustekinumab Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Ustekinumab Injection Revenue by Company (2021-2026)
3.2.2 Global Ustekinumab Injection Revenue Market Share by Company (2021-2026)
3.3 Global Ustekinumab Injection Sale Price by Company
3.4 Key Manufacturers Ustekinumab Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Injection Product Location Distribution
3.4.2 Players Ustekinumab Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Ustekinumab Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ustekinumab Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ustekinumab Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Ustekinumab Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ustekinumab Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ustekinumab Injection Sales Growth
4.4 APAC Ustekinumab Injection Sales Growth
4.5 Europe Ustekinumab Injection Sales Growth
4.6 Middle East & Africa Ustekinumab Injection Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Injection Sales by Country
5.1.1 Americas Ustekinumab Injection Sales by Country (2021-2026)
5.1.2 Americas Ustekinumab Injection Revenue by Country (2021-2026)
5.2 Americas Ustekinumab Injection Sales by Type (2021-2026)
5.3 Americas Ustekinumab Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Injection Sales by Region
6.1.1 APAC Ustekinumab Injection Sales by Region (2021-2026)
6.1.2 APAC Ustekinumab Injection Revenue by Region (2021-2026)
6.2 APAC Ustekinumab Injection Sales by Type (2021-2026)
6.3 APAC Ustekinumab Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab Injection by Country
7.1.1 Europe Ustekinumab Injection Sales by Country (2021-2026)
7.1.2 Europe Ustekinumab Injection Revenue by Country (2021-2026)
7.2 Europe Ustekinumab Injection Sales by Type (2021-2026)
7.3 Europe Ustekinumab Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab Injection by Country
8.1.1 Middle East & Africa Ustekinumab Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ustekinumab Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Ustekinumab Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Ustekinumab Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab Injection
10.3 Manufacturing Process Analysis of Ustekinumab Injection
10.4 Industry Chain Structure of Ustekinumab Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Injection Distributors
11.3 Ustekinumab Injection Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB INJECTION BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Injection Market Size Forecast by Region
12.1.1 Global Ustekinumab Injection Forecast by Region (2027-2032)
12.1.2 Global Ustekinumab Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ustekinumab Injection Forecast by Type (2027-2032)
12.7 Global Ustekinumab Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Meiji
13.1.1 Meiji Company Information
13.1.2 Meiji Ustekinumab Injection Product Portfolios and Specifications
13.1.3 Meiji Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Meiji Main Business Overview
13.1.5 Meiji Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Ustekinumab Injection Product Portfolios and Specifications
13.2.3 Johnson & Johnson Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Alvotech
13.3.1 Alvotech Company Information
13.3.2 Alvotech Ustekinumab Injection Product Portfolios and Specifications
13.3.3 Alvotech Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Alvotech Main Business Overview
13.3.5 Alvotech Latest Developments
13.4 Fuji Pharma
13.4.1 Fuji Pharma Company Information
13.4.2 Fuji Pharma Ustekinumab Injection Product Portfolios and Specifications
13.4.3 Fuji Pharma Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Fuji Pharma Main Business Overview
13.4.5 Fuji Pharma Latest Developments
13.5 Mitsubishi
13.5.1 Mitsubishi Company Information
13.5.2 Mitsubishi Ustekinumab Injection Product Portfolios and Specifications
13.5.3 Mitsubishi Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Mitsubishi Main Business Overview
13.5.5 Mitsubishi Latest Developments
13.6 Tanabe
13.6.1 Tanabe Company Information
13.6.2 Tanabe Ustekinumab Injection Product Portfolios and Specifications
13.6.3 Tanabe Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Tanabe Main Business Overview
13.6.5 Tanabe Latest Developments
13.7 Stada
13.7.1 Stada Company Information
13.7.2 Stada Ustekinumab Injection Product Portfolios and Specifications
13.7.3 Stada Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Stada Main Business Overview
13.7.5 Stada Latest Developments
13.8 EPIRUS
13.8.1 EPIRUS Company Information
13.8.2 EPIRUS Ustekinumab Injection Product Portfolios and Specifications
13.8.3 EPIRUS Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 EPIRUS Main Business Overview
13.8.5 EPIRUS Latest Developments
13.9 BioPharma
13.9.1 BioPharma Company Information
13.9.2 BioPharma Ustekinumab Injection Product Portfolios and Specifications
13.9.3 BioPharma Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BioPharma Main Business Overview
13.9.5 BioPharma Latest Developments
13.10 Formycon
13.10.1 Formycon Company Information
13.10.2 Formycon Ustekinumab Injection Product Portfolios and Specifications
13.10.3 Formycon Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Formycon Main Business Overview
13.10.5 Formycon Latest Developments
13.11 NeuClone
13.11.1 NeuClone Company Information
13.11.2 NeuClone Ustekinumab Injection Product Portfolios and Specifications
13.11.3 NeuClone Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 NeuClone Main Business Overview
13.11.5 NeuClone Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Ustekinumab Injection Product Portfolios and Specifications
13.12.3 Amgen Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Sandoz
13.13.1 Sandoz Company Information
13.13.2 Sandoz Ustekinumab Injection Product Portfolios and Specifications
13.13.3 Sandoz Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sandoz Main Business Overview
13.13.5 Sandoz Latest Developments
13.14 Biocon Biologics
13.14.1 Biocon Biologics Company Information
13.14.2 Biocon Biologics Ustekinumab Injection Product Portfolios and Specifications
13.14.3 Biocon Biologics Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Biocon Biologics Main Business Overview
13.14.5 Biocon Biologics Latest Developments
13.15 Huadong Medicine
13.15.1 Huadong Medicine Company Information
13.15.2 Huadong Medicine Ustekinumab Injection Product Portfolios and Specifications
13.15.3 Huadong Medicine Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Huadong Medicine Main Business Overview
13.15.5 Huadong Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ustekinumab Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ustekinumab Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ustekinumab Injection by Country/Region, 2021, 2025 & 2032
2.2 Ustekinumab Injection Segment by Type
2.2.1 Original Drug
2.2.2 Biosimilars
2.2.3 Ustekinumab Injection Sales by Type
2.2.3.1 Global Ustekinumab Injection Sales Market Share by Type (2021-2026)
2.2.3.2 Global Ustekinumab Injection Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Ustekinumab Injection Sale Price by Type (2021-2026)
2.3 Ustekinumab Injection Segment by Application
2.3.1 Plaque Psoriasis
2.3.2 Psoriatic Arthritis
2.3.3 Crohn’s Disease
2.3.4 Ulcerative Colitis
2.3.5 Others
2.3.6 Ustekinumab Injection Sales by Application
2.3.6.1 Global Ustekinumab Injection Sale Market Share by Application (2021-2026)
2.3.6.2 Global Ustekinumab Injection Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Ustekinumab Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ustekinumab Injection Breakdown Data by Company
3.1.1 Global Ustekinumab Injection Annual Sales by Company (2021-2026)
3.1.2 Global Ustekinumab Injection Sales Market Share by Company (2021-2026)
3.2 Global Ustekinumab Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Ustekinumab Injection Revenue by Company (2021-2026)
3.2.2 Global Ustekinumab Injection Revenue Market Share by Company (2021-2026)
3.3 Global Ustekinumab Injection Sale Price by Company
3.4 Key Manufacturers Ustekinumab Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ustekinumab Injection Product Location Distribution
3.4.2 Players Ustekinumab Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR USTEKINUMAB INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Ustekinumab Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Ustekinumab Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ustekinumab Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ustekinumab Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Ustekinumab Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ustekinumab Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ustekinumab Injection Sales Growth
4.4 APAC Ustekinumab Injection Sales Growth
4.5 Europe Ustekinumab Injection Sales Growth
4.6 Middle East & Africa Ustekinumab Injection Sales Growth
5 AMERICAS
5.1 Americas Ustekinumab Injection Sales by Country
5.1.1 Americas Ustekinumab Injection Sales by Country (2021-2026)
5.1.2 Americas Ustekinumab Injection Revenue by Country (2021-2026)
5.2 Americas Ustekinumab Injection Sales by Type (2021-2026)
5.3 Americas Ustekinumab Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ustekinumab Injection Sales by Region
6.1.1 APAC Ustekinumab Injection Sales by Region (2021-2026)
6.1.2 APAC Ustekinumab Injection Revenue by Region (2021-2026)
6.2 APAC Ustekinumab Injection Sales by Type (2021-2026)
6.3 APAC Ustekinumab Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ustekinumab Injection by Country
7.1.1 Europe Ustekinumab Injection Sales by Country (2021-2026)
7.1.2 Europe Ustekinumab Injection Revenue by Country (2021-2026)
7.2 Europe Ustekinumab Injection Sales by Type (2021-2026)
7.3 Europe Ustekinumab Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ustekinumab Injection by Country
8.1.1 Middle East & Africa Ustekinumab Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ustekinumab Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Ustekinumab Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Ustekinumab Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ustekinumab Injection
10.3 Manufacturing Process Analysis of Ustekinumab Injection
10.4 Industry Chain Structure of Ustekinumab Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ustekinumab Injection Distributors
11.3 Ustekinumab Injection Customer
12 WORLD FORECAST REVIEW FOR USTEKINUMAB INJECTION BY GEOGRAPHIC REGION
12.1 Global Ustekinumab Injection Market Size Forecast by Region
12.1.1 Global Ustekinumab Injection Forecast by Region (2027-2032)
12.1.2 Global Ustekinumab Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ustekinumab Injection Forecast by Type (2027-2032)
12.7 Global Ustekinumab Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Meiji
13.1.1 Meiji Company Information
13.1.2 Meiji Ustekinumab Injection Product Portfolios and Specifications
13.1.3 Meiji Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Meiji Main Business Overview
13.1.5 Meiji Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Ustekinumab Injection Product Portfolios and Specifications
13.2.3 Johnson & Johnson Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Alvotech
13.3.1 Alvotech Company Information
13.3.2 Alvotech Ustekinumab Injection Product Portfolios and Specifications
13.3.3 Alvotech Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Alvotech Main Business Overview
13.3.5 Alvotech Latest Developments
13.4 Fuji Pharma
13.4.1 Fuji Pharma Company Information
13.4.2 Fuji Pharma Ustekinumab Injection Product Portfolios and Specifications
13.4.3 Fuji Pharma Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Fuji Pharma Main Business Overview
13.4.5 Fuji Pharma Latest Developments
13.5 Mitsubishi
13.5.1 Mitsubishi Company Information
13.5.2 Mitsubishi Ustekinumab Injection Product Portfolios and Specifications
13.5.3 Mitsubishi Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Mitsubishi Main Business Overview
13.5.5 Mitsubishi Latest Developments
13.6 Tanabe
13.6.1 Tanabe Company Information
13.6.2 Tanabe Ustekinumab Injection Product Portfolios and Specifications
13.6.3 Tanabe Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Tanabe Main Business Overview
13.6.5 Tanabe Latest Developments
13.7 Stada
13.7.1 Stada Company Information
13.7.2 Stada Ustekinumab Injection Product Portfolios and Specifications
13.7.3 Stada Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Stada Main Business Overview
13.7.5 Stada Latest Developments
13.8 EPIRUS
13.8.1 EPIRUS Company Information
13.8.2 EPIRUS Ustekinumab Injection Product Portfolios and Specifications
13.8.3 EPIRUS Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 EPIRUS Main Business Overview
13.8.5 EPIRUS Latest Developments
13.9 BioPharma
13.9.1 BioPharma Company Information
13.9.2 BioPharma Ustekinumab Injection Product Portfolios and Specifications
13.9.3 BioPharma Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BioPharma Main Business Overview
13.9.5 BioPharma Latest Developments
13.10 Formycon
13.10.1 Formycon Company Information
13.10.2 Formycon Ustekinumab Injection Product Portfolios and Specifications
13.10.3 Formycon Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Formycon Main Business Overview
13.10.5 Formycon Latest Developments
13.11 NeuClone
13.11.1 NeuClone Company Information
13.11.2 NeuClone Ustekinumab Injection Product Portfolios and Specifications
13.11.3 NeuClone Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 NeuClone Main Business Overview
13.11.5 NeuClone Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Ustekinumab Injection Product Portfolios and Specifications
13.12.3 Amgen Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Sandoz
13.13.1 Sandoz Company Information
13.13.2 Sandoz Ustekinumab Injection Product Portfolios and Specifications
13.13.3 Sandoz Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sandoz Main Business Overview
13.13.5 Sandoz Latest Developments
13.14 Biocon Biologics
13.14.1 Biocon Biologics Company Information
13.14.2 Biocon Biologics Ustekinumab Injection Product Portfolios and Specifications
13.14.3 Biocon Biologics Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Biocon Biologics Main Business Overview
13.14.5 Biocon Biologics Latest Developments
13.15 Huadong Medicine
13.15.1 Huadong Medicine Company Information
13.15.2 Huadong Medicine Ustekinumab Injection Product Portfolios and Specifications
13.15.3 Huadong Medicine Ustekinumab Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Huadong Medicine Main Business Overview
13.15.5 Huadong Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ustekinumab Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ustekinumab Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Original Drug
Table 4. Major Players of Biosimilars
Table 5. Global Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 6. Global Ustekinumab Injection Sales Market Share by Type (2021-2026)
Table 7. Global Ustekinumab Injection Revenue by Type (2021-2026) & ($ million)
Table 8. Global Ustekinumab Injection Revenue Market Share by Type (2021-2026)
Table 9. Global Ustekinumab Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Ustekinumab Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Ustekinumab Injection Sale Market Share by Application (2021-2026)
Table 12. Global Ustekinumab Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ustekinumab Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Ustekinumab Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ustekinumab Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Ustekinumab Injection Sales Market Share by Company (2021-2026)
Table 17. Global Ustekinumab Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ustekinumab Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Ustekinumab Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Injection Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Injection Products Offered
Table 22. Ustekinumab Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ustekinumab Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ustekinumab Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ustekinumab Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ustekinumab Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ustekinumab Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ustekinumab Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ustekinumab Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ustekinumab Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ustekinumab Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Ustekinumab Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 37. Americas Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ustekinumab Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ustekinumab Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Ustekinumab Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 42. APAC Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ustekinumab Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 46. Europe Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ustekinumab Injection
Table 52. Key Market Challenges & Risks of Ustekinumab Injection
Table 53. Key Industry Trends of Ustekinumab Injection
Table 54. Ustekinumab Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ustekinumab Injection Distributors List
Table 57. Ustekinumab Injection Customer List
Table 58. Global Ustekinumab Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ustekinumab Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ustekinumab Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ustekinumab Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ustekinumab Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ustekinumab Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ustekinumab Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ustekinumab Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Ustekinumab Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Ustekinumab Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ustekinumab Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Meiji Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Meiji Ustekinumab Injection Product Portfolios and Specifications
Table 74. Meiji Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Meiji Main Business
Table 76. Meiji Latest Developments
Table 77. Johnson & Johnson Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Johnson & Johnson Ustekinumab Injection Product Portfolios and Specifications
Table 79. Johnson & Johnson Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Johnson & Johnson Main Business
Table 81. Johnson & Johnson Latest Developments
Table 82. Alvotech Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Alvotech Ustekinumab Injection Product Portfolios and Specifications
Table 84. Alvotech Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Alvotech Main Business
Table 86. Alvotech Latest Developments
Table 87. Fuji Pharma Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Fuji Pharma Ustekinumab Injection Product Portfolios and Specifications
Table 89. Fuji Pharma Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Fuji Pharma Main Business
Table 91. Fuji Pharma Latest Developments
Table 92. Mitsubishi Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Mitsubishi Ustekinumab Injection Product Portfolios and Specifications
Table 94. Mitsubishi Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Mitsubishi Main Business
Table 96. Mitsubishi Latest Developments
Table 97. Tanabe Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 98. Tanabe Ustekinumab Injection Product Portfolios and Specifications
Table 99. Tanabe Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Tanabe Main Business
Table 101. Tanabe Latest Developments
Table 102. Stada Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 103. Stada Ustekinumab Injection Product Portfolios and Specifications
Table 104. Stada Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Stada Main Business
Table 106. Stada Latest Developments
Table 107. EPIRUS Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 108. EPIRUS Ustekinumab Injection Product Portfolios and Specifications
Table 109. EPIRUS Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. EPIRUS Main Business
Table 111. EPIRUS Latest Developments
Table 112. BioPharma Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 113. BioPharma Ustekinumab Injection Product Portfolios and Specifications
Table 114. BioPharma Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. BioPharma Main Business
Table 116. BioPharma Latest Developments
Table 117. Formycon Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 118. Formycon Ustekinumab Injection Product Portfolios and Specifications
Table 119. Formycon Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Formycon Main Business
Table 121. Formycon Latest Developments
Table 122. NeuClone Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 123. NeuClone Ustekinumab Injection Product Portfolios and Specifications
Table 124. NeuClone Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. NeuClone Main Business
Table 126. NeuClone Latest Developments
Table 127. Amgen Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 128. Amgen Ustekinumab Injection Product Portfolios and Specifications
Table 129. Amgen Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Amgen Main Business
Table 131. Amgen Latest Developments
Table 132. Sandoz Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 133. Sandoz Ustekinumab Injection Product Portfolios and Specifications
Table 134. Sandoz Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Sandoz Main Business
Table 136. Sandoz Latest Developments
Table 137. Biocon Biologics Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 138. Biocon Biologics Ustekinumab Injection Product Portfolios and Specifications
Table 139. Biocon Biologics Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Biocon Biologics Main Business
Table 141. Biocon Biologics Latest Developments
Table 142. Huadong Medicine Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 143. Huadong Medicine Ustekinumab Injection Product Portfolios and Specifications
Table 144. Huadong Medicine Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Huadong Medicine Main Business
Table 146. Huadong Medicine Latest Developments
Table 1. Ustekinumab Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ustekinumab Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Original Drug
Table 4. Major Players of Biosimilars
Table 5. Global Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 6. Global Ustekinumab Injection Sales Market Share by Type (2021-2026)
Table 7. Global Ustekinumab Injection Revenue by Type (2021-2026) & ($ million)
Table 8. Global Ustekinumab Injection Revenue Market Share by Type (2021-2026)
Table 9. Global Ustekinumab Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Ustekinumab Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Ustekinumab Injection Sale Market Share by Application (2021-2026)
Table 12. Global Ustekinumab Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ustekinumab Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Ustekinumab Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ustekinumab Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Ustekinumab Injection Sales Market Share by Company (2021-2026)
Table 17. Global Ustekinumab Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ustekinumab Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Ustekinumab Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ustekinumab Injection Producing Area Distribution and Sales Area
Table 21. Players Ustekinumab Injection Products Offered
Table 22. Ustekinumab Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ustekinumab Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ustekinumab Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ustekinumab Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ustekinumab Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ustekinumab Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ustekinumab Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ustekinumab Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ustekinumab Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ustekinumab Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Ustekinumab Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 37. Americas Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ustekinumab Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ustekinumab Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Ustekinumab Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 42. APAC Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ustekinumab Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 46. Europe Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ustekinumab Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ustekinumab Injection Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Ustekinumab Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ustekinumab Injection
Table 52. Key Market Challenges & Risks of Ustekinumab Injection
Table 53. Key Industry Trends of Ustekinumab Injection
Table 54. Ustekinumab Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ustekinumab Injection Distributors List
Table 57. Ustekinumab Injection Customer List
Table 58. Global Ustekinumab Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ustekinumab Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ustekinumab Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ustekinumab Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ustekinumab Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ustekinumab Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ustekinumab Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ustekinumab Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ustekinumab Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Ustekinumab Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Ustekinumab Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ustekinumab Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Meiji Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Meiji Ustekinumab Injection Product Portfolios and Specifications
Table 74. Meiji Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Meiji Main Business
Table 76. Meiji Latest Developments
Table 77. Johnson & Johnson Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Johnson & Johnson Ustekinumab Injection Product Portfolios and Specifications
Table 79. Johnson & Johnson Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Johnson & Johnson Main Business
Table 81. Johnson & Johnson Latest Developments
Table 82. Alvotech Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Alvotech Ustekinumab Injection Product Portfolios and Specifications
Table 84. Alvotech Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Alvotech Main Business
Table 86. Alvotech Latest Developments
Table 87. Fuji Pharma Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Fuji Pharma Ustekinumab Injection Product Portfolios and Specifications
Table 89. Fuji Pharma Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Fuji Pharma Main Business
Table 91. Fuji Pharma Latest Developments
Table 92. Mitsubishi Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Mitsubishi Ustekinumab Injection Product Portfolios and Specifications
Table 94. Mitsubishi Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Mitsubishi Main Business
Table 96. Mitsubishi Latest Developments
Table 97. Tanabe Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 98. Tanabe Ustekinumab Injection Product Portfolios and Specifications
Table 99. Tanabe Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Tanabe Main Business
Table 101. Tanabe Latest Developments
Table 102. Stada Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 103. Stada Ustekinumab Injection Product Portfolios and Specifications
Table 104. Stada Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Stada Main Business
Table 106. Stada Latest Developments
Table 107. EPIRUS Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 108. EPIRUS Ustekinumab Injection Product Portfolios and Specifications
Table 109. EPIRUS Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. EPIRUS Main Business
Table 111. EPIRUS Latest Developments
Table 112. BioPharma Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 113. BioPharma Ustekinumab Injection Product Portfolios and Specifications
Table 114. BioPharma Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. BioPharma Main Business
Table 116. BioPharma Latest Developments
Table 117. Formycon Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 118. Formycon Ustekinumab Injection Product Portfolios and Specifications
Table 119. Formycon Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Formycon Main Business
Table 121. Formycon Latest Developments
Table 122. NeuClone Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 123. NeuClone Ustekinumab Injection Product Portfolios and Specifications
Table 124. NeuClone Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. NeuClone Main Business
Table 126. NeuClone Latest Developments
Table 127. Amgen Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 128. Amgen Ustekinumab Injection Product Portfolios and Specifications
Table 129. Amgen Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Amgen Main Business
Table 131. Amgen Latest Developments
Table 132. Sandoz Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 133. Sandoz Ustekinumab Injection Product Portfolios and Specifications
Table 134. Sandoz Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Sandoz Main Business
Table 136. Sandoz Latest Developments
Table 137. Biocon Biologics Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 138. Biocon Biologics Ustekinumab Injection Product Portfolios and Specifications
Table 139. Biocon Biologics Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Biocon Biologics Main Business
Table 141. Biocon Biologics Latest Developments
Table 142. Huadong Medicine Basic Information, Ustekinumab Injection Manufacturing Base, Sales Area and Its Competitors
Table 143. Huadong Medicine Ustekinumab Injection Product Portfolios and Specifications
Table 144. Huadong Medicine Ustekinumab Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Huadong Medicine Main Business
Table 146. Huadong Medicine Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ustekinumab Injection
Figure 2. Ustekinumab Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ustekinumab Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ustekinumab Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ustekinumab Injection Sales Market Share by Country/Region (2025)
Figure 10. Ustekinumab Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Original Drug
Figure 12. Product Picture of Biosimilars
Figure 13. Global Ustekinumab Injection Sales Market Share by Type in 2026
Figure 14. Global Ustekinumab Injection Revenue Market Share by Type (2021-2026)
Figure 15. Ustekinumab Injection Consumed in Plaque Psoriasis
Figure 16. Global Ustekinumab Injection Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 17. Ustekinumab Injection Consumed in Psoriatic Arthritis
Figure 18. Global Ustekinumab Injection Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 19. Ustekinumab Injection Consumed in Crohn’s Disease
Figure 20. Global Ustekinumab Injection Market: Crohn’s Disease (2021-2026) & (K Units)
Figure 21. Ustekinumab Injection Consumed in Ulcerative Colitis
Figure 22. Global Ustekinumab Injection Market: Ulcerative Colitis (2021-2026) & (K Units)
Figure 23. Ustekinumab Injection Consumed in Others
Figure 24. Global Ustekinumab Injection Market: Others (2021-2026) & (K Units)
Figure 25. Global Ustekinumab Injection Sale Market Share by Application (2025)
Figure 26. Global Ustekinumab Injection Revenue Market Share by Application in 2026
Figure 27. Ustekinumab Injection Sales by Company in 2026 (K Units)
Figure 28. Global Ustekinumab Injection Sales Market Share by Company in 2026
Figure 29. Ustekinumab Injection Revenue by Company in 2026 ($ millions)
Figure 30. Global Ustekinumab Injection Revenue Market Share by Company in 2026
Figure 31. Global Ustekinumab Injection Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Ustekinumab Injection Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 34. Americas Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 35. APAC Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 36. APAC Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 37. Europe Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 38. Europe Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 41. Americas Ustekinumab Injection Sales Market Share by Country in 2026
Figure 42. Americas Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Figure 43. Americas Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 44. Americas Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 45. United States Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Ustekinumab Injection Sales Market Share by Region in 2026
Figure 50. APAC Ustekinumab Injection Revenue Market Share by Region (2021-2026)
Figure 51. APAC Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 52. APAC Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 53. China Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 57. India Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Ustekinumab Injection Sales Market Share by Country in 2026
Figure 61. Europe Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Figure 62. Europe Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 63. Europe Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 64. Germany Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. France Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Ustekinumab Injection Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 72. Egypt Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Ustekinumab Injection in 2026
Figure 78. Manufacturing Process Analysis of Ustekinumab Injection
Figure 79. Industry Chain Structure of Ustekinumab Injection
Figure 80. Channels of Distribution
Figure 81. Global Ustekinumab Injection Sales Market Forecast by Region (2027-2032)
Figure 82. Global Ustekinumab Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Ustekinumab Injection Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Ustekinumab Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Ustekinumab Injection Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Ustekinumab Injection Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Ustekinumab Injection
Figure 2. Ustekinumab Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ustekinumab Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ustekinumab Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ustekinumab Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ustekinumab Injection Sales Market Share by Country/Region (2025)
Figure 10. Ustekinumab Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Original Drug
Figure 12. Product Picture of Biosimilars
Figure 13. Global Ustekinumab Injection Sales Market Share by Type in 2026
Figure 14. Global Ustekinumab Injection Revenue Market Share by Type (2021-2026)
Figure 15. Ustekinumab Injection Consumed in Plaque Psoriasis
Figure 16. Global Ustekinumab Injection Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 17. Ustekinumab Injection Consumed in Psoriatic Arthritis
Figure 18. Global Ustekinumab Injection Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 19. Ustekinumab Injection Consumed in Crohn’s Disease
Figure 20. Global Ustekinumab Injection Market: Crohn’s Disease (2021-2026) & (K Units)
Figure 21. Ustekinumab Injection Consumed in Ulcerative Colitis
Figure 22. Global Ustekinumab Injection Market: Ulcerative Colitis (2021-2026) & (K Units)
Figure 23. Ustekinumab Injection Consumed in Others
Figure 24. Global Ustekinumab Injection Market: Others (2021-2026) & (K Units)
Figure 25. Global Ustekinumab Injection Sale Market Share by Application (2025)
Figure 26. Global Ustekinumab Injection Revenue Market Share by Application in 2026
Figure 27. Ustekinumab Injection Sales by Company in 2026 (K Units)
Figure 28. Global Ustekinumab Injection Sales Market Share by Company in 2026
Figure 29. Ustekinumab Injection Revenue by Company in 2026 ($ millions)
Figure 30. Global Ustekinumab Injection Revenue Market Share by Company in 2026
Figure 31. Global Ustekinumab Injection Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Ustekinumab Injection Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 34. Americas Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 35. APAC Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 36. APAC Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 37. Europe Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 38. Europe Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Ustekinumab Injection Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Ustekinumab Injection Revenue 2021-2026 ($ millions)
Figure 41. Americas Ustekinumab Injection Sales Market Share by Country in 2026
Figure 42. Americas Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Figure 43. Americas Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 44. Americas Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 45. United States Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Ustekinumab Injection Sales Market Share by Region in 2026
Figure 50. APAC Ustekinumab Injection Revenue Market Share by Region (2021-2026)
Figure 51. APAC Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 52. APAC Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 53. China Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 57. India Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Ustekinumab Injection Sales Market Share by Country in 2026
Figure 61. Europe Ustekinumab Injection Revenue Market Share by Country (2021-2026)
Figure 62. Europe Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 63. Europe Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 64. Germany Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. France Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Ustekinumab Injection Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Ustekinumab Injection Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Ustekinumab Injection Sales Market Share by Application (2021-2026)
Figure 72. Egypt Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Ustekinumab Injection Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Ustekinumab Injection in 2026
Figure 78. Manufacturing Process Analysis of Ustekinumab Injection
Figure 79. Industry Chain Structure of Ustekinumab Injection
Figure 80. Channels of Distribution
Figure 81. Global Ustekinumab Injection Sales Market Forecast by Region (2027-2032)
Figure 82. Global Ustekinumab Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Ustekinumab Injection Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Ustekinumab Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Ustekinumab Injection Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Ustekinumab Injection Revenue Market Share Forecast by Application (2027-2032)
